- NCIt
- C7707
Loading cancer entity…
Loading cancer entity…
Clinical trials
76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (15)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT01034566 |
| Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma |
| withdrawn |
| N/A |
| 0 |
| Abramson Cancer Center at Penn MedicineOTHER |
| 1 |
| Jun 10, 2021 |
| clinicaltrials |
| NCT03613259 | Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jun 9, 2020 | clinicaltrials |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma | withdrawn | N/A | 0 | Albert Einstein College of MedicineOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00017160 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 27, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2025source: clinicaltrials